Brief Summary
This study will compare the effectiveness of best available surgical treatment with best available endovascular treatment in adults with critical limb ischemia (CLI) who are eligible for both treatment options.
Brief Title
Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
Detailed Description
Male and female subjects aged 18 years or older will be randomized to receive either open surgical treatment or endovascular treatment. They will be followed for at least 2 years and up to 4 years and 2 months after treatment to primarily assess survival and major adverse limb events in the index or treated limb, and secondarily, to determine clinical and cost effectiveness outcomes after treatment. These outcomes (survival-free of major limb events and clinical, functional and cost effectiveness) will be compared within two cohorts of subjects: those with an available single-segment great saphenous vein, and those with an alternative conduit. The null hypotheses for both cohorts is that there will be no difference in MALE-free survival between best endovascular therapy and best surgical therapy.
Completion Date
Completion Date Type
Actual
Conditions
Critical Limb Ischemia
Eligibility Criteria
Inclusion Criteria:
1. Male or female, age 18 years or older.
2. Infrainguinal PAOD (occlusive disease of the arteries below the inguinal ligament).
3. CLI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6.
4. Candidate for both endovascular and open infrainguinal revascularization as judged by the treating investigators
5. Adequate aortoiliac inflow.
6. Adequate popliteal, tibial or pedal revascularization target defined as an infrainguinal arterial segment distal to the area of stenosis/occlusion which can support a distal anastomosis of a surgical bypass.
7. Willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.
Exclusion Criteria:
1. Presence of a popliteal aneurysm (\>2 cm) in the index limb.
2. Life expectancy of less than 2 years due to reasons other than PAOD.
3. Excessive risk for surgical bypass (as determined by the operating surgeon and the CLI Team)
4. Planned above ankle amputation on ipsilateral limb within 4 weeks of index procedure.
5. Active vasculitis, Buerger's disease, or acute limb-threatening ischemia
6. Any prior index limb infrainguinal stenting or stent grafting associated with significant restenosis within 1 cm of stent or stent-graft, unless the occlusion/restenosis site is outside the intended treatment zone (i.e.,. a tibial vessel that is not currently intended to be revascularized as a part of the treatment for CLI).
7. Any of the following procedures performed on the index limb within 3 months prior to enrollment:
1. Infrainguinal balloon angioplasty, atherectomy, stent, or stentgraft;
2. Infrainguinal bypass with either venous or prosthetic conduit
8. Open surgical inflow procedure (aortofemoral, axillofemoral, iliofemoral, thoracofemoral or femorofemoral bypass) within 6 weeks prior to enrollment
9. Current chemotherapy or radiation therapy.
10. Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid reaction (laryngospasm, bronchospasm, cardiorespiratory collapse, or equivalent) which would preclude patient participation in angiographic procedures.
11. Pregnancy or lactation.
12. Administration of an investigational drug for PAD within 30 days of randomization.
13. Participation in a clinical trial (except observational studies) within the previous 30 days.
14. Prior enrollment or randomization into BEST-CLI.
1. Male or female, age 18 years or older.
2. Infrainguinal PAOD (occlusive disease of the arteries below the inguinal ligament).
3. CLI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6.
4. Candidate for both endovascular and open infrainguinal revascularization as judged by the treating investigators
5. Adequate aortoiliac inflow.
6. Adequate popliteal, tibial or pedal revascularization target defined as an infrainguinal arterial segment distal to the area of stenosis/occlusion which can support a distal anastomosis of a surgical bypass.
7. Willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.
Exclusion Criteria:
1. Presence of a popliteal aneurysm (\>2 cm) in the index limb.
2. Life expectancy of less than 2 years due to reasons other than PAOD.
3. Excessive risk for surgical bypass (as determined by the operating surgeon and the CLI Team)
4. Planned above ankle amputation on ipsilateral limb within 4 weeks of index procedure.
5. Active vasculitis, Buerger's disease, or acute limb-threatening ischemia
6. Any prior index limb infrainguinal stenting or stent grafting associated with significant restenosis within 1 cm of stent or stent-graft, unless the occlusion/restenosis site is outside the intended treatment zone (i.e.,. a tibial vessel that is not currently intended to be revascularized as a part of the treatment for CLI).
7. Any of the following procedures performed on the index limb within 3 months prior to enrollment:
1. Infrainguinal balloon angioplasty, atherectomy, stent, or stentgraft;
2. Infrainguinal bypass with either venous or prosthetic conduit
8. Open surgical inflow procedure (aortofemoral, axillofemoral, iliofemoral, thoracofemoral or femorofemoral bypass) within 6 weeks prior to enrollment
9. Current chemotherapy or radiation therapy.
10. Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid reaction (laryngospasm, bronchospasm, cardiorespiratory collapse, or equivalent) which would preclude patient participation in angiographic procedures.
11. Pregnancy or lactation.
12. Administration of an investigational drug for PAD within 30 days of randomization.
13. Participation in a clinical trial (except observational studies) within the previous 30 days.
14. Prior enrollment or randomization into BEST-CLI.
Inclusion Criteria
Inclusion Criteria:
1. Male or female, age 18 years or older.
2. Infrainguinal PAOD (occlusive disease of the arteries below the inguinal ligament).
3. CLI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6.
4. Candidate for both endovascular and open infrainguinal revascularization as judged by the treating investigators
5. Adequate aortoiliac inflow.
6. Adequate popliteal, tibial or pedal revascularization target defined as an infrainguinal arterial segment distal to the area of stenosis/occlusion which can support a distal anastomosis of a surgical bypass.
7. Willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.
1. Male or female, age 18 years or older.
2. Infrainguinal PAOD (occlusive disease of the arteries below the inguinal ligament).
3. CLI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6.
4. Candidate for both endovascular and open infrainguinal revascularization as judged by the treating investigators
5. Adequate aortoiliac inflow.
6. Adequate popliteal, tibial or pedal revascularization target defined as an infrainguinal arterial segment distal to the area of stenosis/occlusion which can support a distal anastomosis of a surgical bypass.
7. Willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.
Gender
All
Gender Based
false
Keywords
Surgical revascularization
Endovascular revascularization
Amputation
Peripheral artery disease
Critical limb ischemia
claudication
leg pain
leg ulcer
gangrene
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Minimum Age
18 Years
NCT Id
NCT02060630
Org Class
Other
Org Full Name
Carelon Research
Org Study Id
BEST-CLI Trial
Overall Status
Completed
Phases
Not Applicable
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia
Primary Outcomes
Outcome Description
* Time to major adverse limb event or death, whichever occurs first in subjects with Single-Segment Great Saphenous Vein (SSGSV) available
* Time to major adverse limb event or death, whichever occurs first in subjects without available SSGSV
* Time to major adverse limb event or death, whichever occurs first in subjects without available SSGSV
Outcome Measure
The primary efficacy endpoint: MALE (Major Adverse Limb Event)-free survival. MALE is defined as above ankle amputation of the index limb or major re-intervention (e.g. new bypass graft, jump/interposition graft revision, or thrombectomy/ thrombolysis)
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Secondary Ids
Secondary Id
1U01HL107407
Secondary Outcomes
Outcome Description
Time to re-intervention of the index leg, above ankle amputation of the index leg, or death, whichever occurs first in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Re-intervention and amputation-free survival (cohort 1)
Outcome Description
Time to re-intervention of the index leg, above ankle amputation of the index leg, or death, whichever occurs first in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Re-intervention and amputation-free survival (cohort 2)
Outcome Description
Time to re-intervention of the index leg, amputation of the index leg, or death within 30 days of index procedure, whichever occurs first in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from MALE-POD (POD, defined as death within 30 days of index procedure) (cohort 1)
Outcome Description
Time to re-intervention of the index leg, amputation of the index leg, or death within 30 days of index procedure, whichever occurs first in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Clinical: Freedom from MALE-POD (POD, defined as death within 30 days of index procedure) (cohort 2)
Outcome Description
Time to amputation of the index leg, or death, whichever occurs first in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Amputation-free survival (cohort 1)
Outcome Description
Time to amputation of the index leg, or death, whichever occurs first in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Amputation-free survival (cohort 2)
Outcome Description
Time to death within 30 days of index procedure in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from POD (POD, defined as death within 30 days of index procedure) (cohort 1)
Outcome Description
Time to death within 30 days of index procedure in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom POD (POD, defined as death within 30 days of index procedure) (cohort 2)
Outcome Description
Time to myocardial infarction (MI) in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from Myocardial Infarction (cohort 1)
Outcome Description
Time to myocardial infarction (MI) in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from Myocardial Infarction (cohort 2)
Outcome Description
Time to stroke in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from Stroke (cohort 1)
Outcome Description
Time to stroke in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from Stroke (cohort 2)
Outcome Description
Time to re-intervention (major and minor) in index leg in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from re-intervention (major and minor) in index leg (cohort 1)
Outcome Description
Time to re-intervention (major and minor) in index leg in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from re-intervention (major and minor) in index leg (cohort 2)
Outcome Description
Number of re-interventions (major and minor) in per limb salvaged in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Number of re-interventions (major and minor) in per limb salvaged (cohort 1)
Outcome Description
Number of re-interventions (major and minor) in per limb salvaged in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Number of re-interventions (major and minor) in per limb salvaged (cohort 2)
Outcome Description
Time to hemodynamic failure in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from hemodynamic failure (cohort 1)
Outcome Description
Time to hemodynamic failure in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from hemodynamic failure (cohort 2)
Outcome Description
Time to above ankle amputation, major reintervention, MALE, degradation of WIfI stage or death, whichever occurs first in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from clinical failure (cohort 1)
Outcome Description
Time to above ankle amputation, major reintervention, MALE, degradation of WIfI stage or death, whichever occurs first in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from clinical failure (cohort 2)
Outcome Description
Time to resolution of presenting CLI symptoms in the index limb in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from Critical Limb Ischemia (CLI) (cohort 1)
Outcome Description
Time to resolution of presenting CLI symptoms in the index limb in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from Critical Limb Ischemia (CLI) (cohort 2)
Outcome Description
Time to all-cause mortality in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from all-cause mortality (cohort 1)
Outcome Description
Time to all-cause mortality in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Clinical: Freedom from all-cause mortality (cohort 2)
Outcome Description
VasuQOL measurements in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Quality of Life assessment using VasuQoL (cohort 1)
Outcome Description
VasuQOL measurements in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Quality of Life assessment using VasuQoL (cohort 2)
Outcome Description
EuroQOL measurements in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Quality of Life assessment using EuroQoL (cohort 1)
Outcome Description
EuroQOL measurements in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Quality of Life assessment using EuroQoL (cohort 2)
Outcome Description
Physical Component Summary (PCS) scores in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Function assessment using SF-12, PCS (cohort 1)
Outcome Description
Physical Component Summary (PCS) scores in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Function assessment using SF-12, PCS (cohort 2)
Outcome Description
Mental Component Summary (MCS) scores in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Function assessment using SF-12, MCS (cohort 1)
Outcome Description
Mental Component Summary (MCS) scores in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Function assessment using SF-12, MCS (cohort 2)
Outcome Description
Utility Index (SF-6D R2) scores in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Function assessment using SF-12, SF-6D R2 (cohort 1)
Outcome Description
Utility Index (SF-6D R2) scores in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Function assessment using SF-12, SF-6D R2(cohort 2)
Outcome Description
Scores for Pain Now in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Pain Now (cohort 1)
Outcome Description
Scores for Pain Now in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Pain Now (cohort 2)
Outcome Description
Scores for Usual level of Pain during the last week in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Usual level of Pain (cohort 1)
Outcome Description
Scores for Usual level of Pain during the last week in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Usual level of Pain (cohort 2)
Outcome Description
Scores for Best level of Pain during the last week in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Best level of Pain (cohort 1)
Outcome Description
Scores for Best level of Pain during the last week in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Best level of Pain (cohort 2)
Outcome Description
Scores for Worst level of Pain during the last week in subjects with SSGSV available
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Worst level of Pain (cohort 1)
Outcome Description
Scores for Worst level of Pain during the last week in subjects without available SSGSV
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Functional: Numerical rating scale for Pain, Worst level of Pain (cohort 2)
Outcome Description
Six-minute walk test measurements in subjects with SSGSV available. The six-minute walk test was performed at a subset of clinical sites (for whom this test was standard of care) and was limited to patients for whom rest pain, wounds, or foot surgery (recent or anticipated) did not preclude weight bearing
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Function: Six-minute walk test (cohort 1)
Outcome Description
Six-minute walk test measurements in subjects without available SSGSV. The six-minute walk test was performed at a subset of clinical sites (for whom this test was standard of care) and was limited to patients for whom rest pain, wounds, or foot surgery (recent or anticipated) did not preclude weight bearing
Outcome Time Frame
Through each subject's last regularly scheduled study visit, up to a maximum of 84 months per subject
Outcome Measure
Function: Six-minute walk test (cohort 2)
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Evan Lipsitz
Investigator Email
elipsitz@montefiore.org
Investigator Phone
Categories Mesh Debug
Heart/Cardiovascular --- ARTERIOSCLEROSIS
Heart/Cardiovascular --- ARTERIAL OCCLUSIVE DISEASES
Blood & Bone Marrow Cancers --- VASCULAR DISEASES
Heart/Cardiovascular --- VASCULAR DISEASES
Blood Disorders --- CARDIOVASCULAR DISEASES
Blood & Bone Marrow Cancers --- CARDIOVASCULAR DISEASES
Heart/Cardiovascular --- CARDIOVASCULAR DISEASES
Heart/Cardiovascular --- ISCHEMIA
MeSH Terms
CHRONIC LIMB-THREATENING ISCHEMIA
PERIPHERAL ARTERIAL DISEASE
INTERMITTENT CLAUDICATION
LEG ULCER
GANGRENE
ATHEROSCLEROSIS
ARTERIOSCLEROSIS
ARTERIAL OCCLUSIVE DISEASES
VASCULAR DISEASES
CARDIOVASCULAR DISEASES
PERIPHERAL VASCULAR DISEASES
CHRONIC DISEASE
DISEASE ATTRIBUTES
PATHOLOGIC PROCESSES
PATHOLOGICAL CONDITIONS, SIGNS AND SYMPTOMS
ISCHEMIA
SIGNS AND SYMPTOMS
SKIN ULCER
SKIN DISEASES
SKIN AND CONNECTIVE TISSUE DISEASES
NECROSIS